vs
Royalty Pharma plc（RPRX）与SCANSOURCE, INC.（SCSC）财务数据对比。点击上方公司名可切换其他公司
SCANSOURCE, INC.的季度营收约是Royalty Pharma plc的1.2倍（$766.5M vs $622.0M），Royalty Pharma plc净利率更高（34.4% vs 2.2%，领先32.3%），Royalty Pharma plc同比增速更快（4.8% vs 2.5%），过去两年Royalty Pharma plc的营收复合增速更高（4.6% vs 0.9%）
本公司是总部位于美国马萨诸塞州剑桥市的临床阶段生物制药企业，专注于研发可调节转化生长因子β（TGF-β）超家族蛋白的药物，该类蛋白在红细胞、肌肉、骨骼、血管等细胞与组织的生长修复过程中发挥核心作用。
ScanSource是全球领先的专业技术分销商，主营销售点系统、条码扫描设备、网络安全产品、云服务及通信解决方案，面向北美、拉美、欧洲的增值经销商、服务提供商及企业客户，覆盖零售、医疗、工业、公共部门等领域。
RPRX vs SCSC — 直观对比
营收规模更大
SCSC
是对方的1.2倍
$622.0M
营收增速更快
RPRX
高出2.2%
2.5%
净利率更高
RPRX
高出32.3%
2.2%
两年增速更快
RPRX
近两年复合增速
0.9%
损益表 — Q4 FY2025 vs Q2 FY2026
| 指标 | | |
|---|---|---|
| 营收 | $622.0M | $766.5M |
| 净利润 | $214.2M | $16.5M |
| 毛利率 | — | 13.4% |
| 营业利润率 | 62.4% | 2.3% |
| 净利率 | 34.4% | 2.2% |
| 营收同比 | 4.8% | 2.5% |
| 净利润同比 | 2.9% | -3.3% |
| 每股收益（稀释后） | $0.49 | $0.75 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收RPRXSCSC
| Q4 25 | $622.0M | $766.5M | ||
| Q3 25 | $609.3M | $739.6M | ||
| Q2 25 | $578.7M | $812.9M | ||
| Q1 25 | $568.2M | $704.8M | ||
| Q4 24 | $593.6M | $747.5M | ||
| Q3 24 | $564.7M | $775.6M | ||
| Q2 24 | $537.3M | $746.1M | ||
| Q1 24 | $568.0M | $752.6M |
净利润RPRXSCSC
| Q4 25 | $214.2M | $16.5M | ||
| Q3 25 | $288.2M | $19.9M | ||
| Q2 25 | $30.2M | $20.1M | ||
| Q1 25 | $238.3M | $17.4M | ||
| Q4 24 | $208.2M | $17.1M | ||
| Q3 24 | $544.0M | $17.0M | ||
| Q2 24 | $102.0M | $16.1M | ||
| Q1 24 | $4.8M | $12.8M |
毛利率RPRXSCSC
| Q4 25 | — | 13.4% | ||
| Q3 25 | — | 14.5% | ||
| Q2 25 | — | 12.9% | ||
| Q1 25 | — | 14.2% | ||
| Q4 24 | — | 13.6% | ||
| Q3 24 | — | 13.1% | ||
| Q2 24 | — | 13.0% | ||
| Q1 24 | — | 12.6% |
营业利润率RPRXSCSC
| Q4 25 | 62.4% | 2.3% | ||
| Q3 25 | 70.1% | 3.5% | ||
| Q2 25 | 36.3% | 3.3% | ||
| Q1 25 | 94.0% | 3.2% | ||
| Q4 24 | 60.9% | 2.5% | ||
| Q3 24 | — | 2.3% | ||
| Q2 24 | 50.2% | 2.9% | ||
| Q1 24 | -13.0% | 2.3% |
净利率RPRXSCSC
| Q4 25 | 34.4% | 2.2% | ||
| Q3 25 | 47.3% | 2.7% | ||
| Q2 25 | 5.2% | 2.5% | ||
| Q1 25 | 41.9% | 2.5% | ||
| Q4 24 | 35.1% | 2.3% | ||
| Q3 24 | 96.3% | 2.2% | ||
| Q2 24 | 19.0% | 2.2% | ||
| Q1 24 | 0.8% | 1.7% |
每股收益（稀释后）RPRXSCSC
| Q4 25 | $0.49 | $0.75 | ||
| Q3 25 | $0.67 | $0.89 | ||
| Q2 25 | $0.07 | $0.87 | ||
| Q1 25 | $0.55 | $0.74 | ||
| Q4 24 | $0.46 | $0.70 | ||
| Q3 24 | $1.21 | $0.69 | ||
| Q2 24 | $0.23 | $0.66 | ||
| Q1 24 | $0.01 | $0.50 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $618.7M | $83.5M |
| 总债务越低越好 | $9.0B | — |
| 股东权益账面价值 | $9.7B | $910.9M |
| 总资产 | $19.6B | $1.7B |
| 负债/权益比越低杠杆越低 | 0.92× | — |
8季度趋势，按日历期对齐
现金及短期投资RPRXSCSC
| Q4 25 | $618.7M | $83.5M | ||
| Q3 25 | $938.9M | $124.9M | ||
| Q2 25 | $631.9M | $126.2M | ||
| Q1 25 | $1.1B | $146.3M | ||
| Q4 24 | $929.0M | $110.5M | ||
| Q3 24 | $950.1M | $145.0M | ||
| Q2 24 | $1.8B | $185.5M | ||
| Q1 24 | $843.0M | $159.1M |
总债务RPRXSCSC
| Q4 25 | $9.0B | — | ||
| Q3 25 | $8.9B | — | ||
| Q2 25 | $8.0B | — | ||
| Q1 25 | $7.6B | — | ||
| Q4 24 | $7.6B | — | ||
| Q3 24 | $7.6B | — | ||
| Q2 24 | $7.6B | — | ||
| Q1 24 | $6.1B | — |
股东权益RPRXSCSC
| Q4 25 | $9.7B | $910.9M | ||
| Q3 25 | $9.6B | $914.0M | ||
| Q2 25 | $9.5B | $906.4M | ||
| Q1 25 | $9.8B | $901.7M | ||
| Q4 24 | $10.3B | $900.7M | ||
| Q3 24 | $10.3B | $920.9M | ||
| Q2 24 | $9.8B | $924.3M | ||
| Q1 24 | $9.9B | $944.1M |
总资产RPRXSCSC
| Q4 25 | $19.6B | $1.7B | ||
| Q3 25 | $19.3B | $1.7B | ||
| Q2 25 | $18.3B | $1.8B | ||
| Q1 25 | $17.6B | $1.7B | ||
| Q4 24 | $18.2B | $1.7B | ||
| Q3 24 | $18.0B | $1.8B | ||
| Q2 24 | $17.7B | $1.8B | ||
| Q1 24 | $16.1B | $1.8B |
负债/权益比RPRXSCSC
| Q4 25 | 0.92× | — | ||
| Q3 25 | 0.93× | — | ||
| Q2 25 | 0.84× | — | ||
| Q1 25 | 0.78× | — | ||
| Q4 24 | 0.74× | — | ||
| Q3 24 | 0.74× | — | ||
| Q2 24 | 0.78× | — | ||
| Q1 24 | 0.62× | — |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $827.1M | $30.8M |
| 自由现金流经营现金流 - 资本支出 | — | $28.9M |
| 自由现金流率自由现金流/营收 | — | 3.8% |
| 资本支出强度资本支出/营收 | — | 0.3% |
| 现金转化率经营现金流/净利润 | 3.86× | 1.87× |
| 过去12个月自由现金流最近4个季度 | — | — |
8季度趋势，按日历期对齐
经营现金流RPRXSCSC
| Q4 25 | $827.1M | $30.8M | ||
| Q3 25 | $702.6M | $23.2M | ||
| Q2 25 | $364.0M | — | ||
| Q1 25 | $596.1M | $66.1M | ||
| Q4 24 | $742.5M | $-6.2M | ||
| Q3 24 | $703.6M | $44.8M | ||
| Q2 24 | $658.2M | — | ||
| Q1 24 | $664.6M | $160.2M |
自由现金流RPRXSCSC
| Q4 25 | — | $28.9M | ||
| Q3 25 | — | $20.8M | ||
| Q2 25 | — | — | ||
| Q1 25 | — | $64.6M | ||
| Q4 24 | — | $-8.2M | ||
| Q3 24 | — | $42.5M | ||
| Q2 24 | — | — | ||
| Q1 24 | — | $157.7M |
自由现金流率RPRXSCSC
| Q4 25 | — | 3.8% | ||
| Q3 25 | — | 2.8% | ||
| Q2 25 | — | — | ||
| Q1 25 | — | 9.2% | ||
| Q4 24 | — | -1.1% | ||
| Q3 24 | — | 5.5% | ||
| Q2 24 | — | — | ||
| Q1 24 | — | 21.0% |
资本支出强度RPRXSCSC
| Q4 25 | — | 0.3% | ||
| Q3 25 | — | 0.3% | ||
| Q2 25 | — | 0.3% | ||
| Q1 25 | — | 0.2% | ||
| Q4 24 | — | 0.3% | ||
| Q3 24 | — | 0.3% | ||
| Q2 24 | — | 0.2% | ||
| Q1 24 | — | 0.3% |
现金转化率RPRXSCSC
| Q4 25 | 3.86× | 1.87× | ||
| Q3 25 | 2.44× | 1.17× | ||
| Q2 25 | 12.06× | — | ||
| Q1 25 | 2.50× | 3.79× | ||
| Q4 24 | 3.57× | -0.36× | ||
| Q3 24 | 1.29× | 2.64× | ||
| Q2 24 | 6.45× | — | ||
| Q1 24 | 139.10× | 12.51× |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
RPRX
| Financial Royalty Assets | $592.4M | 95% |
| Royalty Income Other | $29.6M | 5% |
SCSC
| Products And Services | $723.4M | 94% |
| Intelisys Advisory | $25.0M | 3% |
| Recurring Revenue | $18.2M | 2% |
